Fed. Circ. Affirms $107M Inhaler IP Judgment Against GSK
The Federal Circuit on Thursday rejected GlaxoSmithKline LLC's argument that it should get a new damages trial in an intellectual property case, affirming a Delaware federal jury verdict that GSK's Ellipta...To view the full article, register now.
Already a subscriber? Click here to view full article